First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial

Journal:

Nature Medicine

Published:

2025-08-19

DOI:

10.1038/s41591-025-03883-5

Affiliations:

21

Authors:

23

Go to article

Institutions	Authors	Share
State Key Laboratory of Oncology in South China, SYSUCC, China	3.000000	0.13
Sichuan Kelun Pharmaceutical Co., Ltd., China	2.500000	0.11
Hunan Cancer Hospital, China	2.000000	0.09
Jilin Province Cancer Hospital, China	1.000000	0.04
The First Hospital of China Medical University, China	1.000000	0.04
Shanxi Cancer Hospital, China	1.000000	0.04
West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), SCU, China	1.000000	0.04
First Affiliated Hospital, ZZU, China	1.000000	0.04
Harbin Medical University Cancer Hospital, China	1.000000	0.04
Hubei Cancer Hospital (HBCH), China	1.000000	0.04
Hospital and Cancer Center, CQU, China	1.000000	0.04
The Second Affiliated Hospital to Nanchang University, China	1.000000	0.04
Shandong Cancer Hospital, China	1.000000	0.04
Zhejiang Cancer Hospital (ZJCH), China	1.000000	0.04
The First Affiliated Hospital of Xiamen University, China	1.000000	0.04
Jiangsu Provincial People's Hospital (The First Affiliated Hospital of Nanjing Medical University), China	1.000000	0.04
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	1.000000	0.04
Henan Cancer Hospital, ZZU, China	0.666667	0.03
National Engineering Research Centre of Targeted Biologics, China	0.500000	0.02
Henan Academy of Innovations in Medical Science, China	0.333333	0.01

Interested in Oncology and Carcinogenesis?